Potential Vaccine for HIV Faces Many Dilemmas

Recommend to others!

Up to this date, the number of individuals who are getting infected by the HIV infection causing virus is still on the rise. This is despite the fact that many government states have already launched many methods and strategies in order to boosts the fight against HIV infection. Additional funds as well have been released which deemed to help those individuals who cannot afford to be treated with anti-retroviral drugs which seemed to be expensive, and to further relay information to the general populations about the ways on how to prevent the spread of the virus. In addition, many researchers and scientists are continuing to invest their time and efforts in conducting further studies in an attempt to discover a vaccine which can enhance the immune system of the general public and protect them from the virus causing HIV infection.

In fact, a study which ought to discover a vaccine which can fight against the virus of HIV infection has been conducted by several researchers. However, the said study known as the STEP study was halted in the year 2007 because of some dilemmas that the researchers found out after trials. The problem according to the researcher was that they discovered after interim analysis that the potential vaccine which is supposed to protect the general public against HIV infection is not working and not effective. Hence, the researchers decided to stop the clinical trial testing back in September 2007.

In addition, other group of scientists and experts discovered new problems about the use of the potential HIV vaccine which further intensified the stopping of the clinical trials of the said vaccine. The group of researchers was led by Juliana McElrath, at the Fred Hutchinson Cancer Research Center, Seattle.

According to the succeeding analysis made by the researchers from the STEP study, the problem with the vaccine goes beyond its being ineffective, but more so, researchers found out that those individuals who got the vaccine were made even more susceptible of having the HIV infection, especially among those individuals who had pre-existing immune effectors or antibodies in which these antibodies had recognized the Ad5 component of the vaccine.

Moreover, the researchers found out that the large numbers of immune cells responsive to the Ad5 of those individuals from the STEP study had a less vigorous response to the HIV causing virus. That is compared among those individuals who had less number of immune cells responsive to Ad5 before the vaccination was enacted.

 

 

Comments

comments

Speak Your Mind

*

Current day month ye@r *